1. Jiaying Lyu, Tianjian Zhou, Shijie Yuan, Wentian Guo, and Yuan Ji.(2020) MUCE: Bayesian Hierarchical Modeling for the Design and Analysis of Phase 1b Multiple Expansion Cohort Trials. Under review.
  2. Tianjian Zhou, Wentian Guo, Yuan Ji. (2019) PoD-TPI: Probability-of-Decision Toxicity Probability Interval Design to Accelerate Phase I Trials. Statistics in Biosciences. Accepted.
  3. Ciara Nugent, Wentian Guo, Perter Mueller, Yuan Ji. (2019) Bayesian Approaches to Subgroup Analysis and Related Adaptive Clinical Trial Design. JCO Precision Oncology. Accepted.
  4. Zhou,T., Guo, W., & Ji, Y. (2019). PoD-TPI: Probability-of-DecisionToxicity Probability Interval Design to Accelerate Phase I Trials. arXivpreprint arXiv:1904.12981.
  5. Liu, M., Wang, S.J. and Ji, Y., (2019). The i3+3 design for phase I clinical trials. Journal of Biopharmaceutical Statistics
  6. Guo, W., Ji, Y., & Li, D. (2019). R-TPI: rolling toxicity probability interval design to shorten the duration and maintain safety of phase I trials. Journal of biopharmaceutical statistics, 1-14.
  7. Lyu, J., Curran, E., & Ji, Y. (2018). Bayesian Adaptive Design for Finding the Maximum Tolerated Sequence of Doses in Multicycle Dose-Finding Clinical Trials. JCO Precision Oncology, 2, 1-19.
  8. Lyu, J., Ji, Y., Zhao, N., & Catenacci, D. V. (2019). AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual‐agent dose finding trials. Journal of the Royal Statistical Society: Series C (Applied Statistics), 68(2), 385-410.
  9. Guo, W., Ji, Y., & Catenacci, D. V. (2017). A subgroup cluster‐based Bayesian adaptive design for precision medicine. Biometrics, 73(2), 367-377.
  10. Guo, W., Wang, S. J., Yang, S., Lynn, H., & Ji, Y. (2017). A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2. Contemporary clinical trials, 58, 23-33.
  11. Lee, J., Thall, P. F., Ji, Y., & Müller, P. (2016). A decision-theoretic phase I–II design for ordinal outcomes in two cycles. Biostatistics, 17(2), 304-319.
  12. Li, D. H., Whitmore, J. B., Guo, W., & Ji, Y. (2016). Toxicity and Efficacy Probability Interval Design for Phase 1 Adoptive Cell Therapy Dose-Finding Clinical Trials. Clinical Cancer Research, clincanres-1125.
  13. Yang, S., Wang, S. J., & Ji, Y. (2015). An integrated dose-finding tool for phase I trials in oncology. Contemporary clinical trials, 45, 426-434.
  14. Guo, W., Ni, Y., & Ji, Y. (2015). TEAMS: Toxicity-and efficacy-based dose-insertion design with adaptive model selection for phase I/II dose-escalation trials in oncology. Statistics in biosciences, 7(2), 432-459.
  15. Lee, J., Thall, P. F., Ji, Y., & Müller, P. (2015). Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity. Journal of the American Statistical Association, 110(510), 711-722.
  16. Xu, Y., Trippa, L., Müller, P., & Ji, Y. (2016). Subgroup-based adaptive (suba) designs for multi-arm biomarker trials. Statistics in biosciences, 8(1), 159-180.
  17. Pan, H., Xie, F., Liu, P., Xia, J., & Ji, Y. (2014). A phase I/II seamless dose escalation/expansion with adaptive randomization scheme (SEARS). Clinical Trials, 11(1), 49-59.
  18. Cai, C., Yuan, Y., & Ji, Y. (2014). A Bayesian dose finding design for oncology clinical trials of combinational biological agents. Journal of the Royal Statistical Society: Series C (Applied Statistics), 63(1), 159-173.
  19. Ji, Y., & Wang, S. J. (2013). Modified toxicity probability interval design: a safer and more reliable method than the 3+ 3 design for practical phase I trials. Journal of Clinical Oncology, 31(14), 1785.
  20. Ji, Y., & Wang, S. J. (2013). Safety concerns of the 3+ 3 design: A comparison to the mTPI design. In Topics in Applied Statistics (pp. 125-135). Springer, New York, NY.
  21. Pan, H., Ji, Y., Chen, Z., Li, C., & Xia, J. (2013). The choice of phase I bayesian adaptive designs in china. International Journal of Drug Discovery, 5(1), 185.
  22. Xie, F., Ji, Y., & Tremmel, L. (2012). A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I/II trials. Contemporary clinical trials, 33(4), 739-748.
  23. Ji, Y., Feng, L., Liu, P., Shpall, E. J., Kebriaei, P., Champlin, R., ... & Cooper, L. J. (2012). Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. Journal of biopharmaceutical statistics, 22(6), 1206-1219.
  24. Younes, A., Oki, Y., Bociek, R. G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., Li, Z., Drouin, M., Patterson, T., Ward, M. R., Paulus, J. K., Ji, Y., Medeiros, L. J., & Li, Z. (2011). Phase II Study of Mocetinostat (MGCD0103) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. The Lancet. Oncology, 12(13), 1222.
  25. Hu, B., Bekele, B. N., & Ji, Y. (2013). Adaptive dose insertion in early phase clinical trials. Clinical Trials, 10(2), 216-224.
  26. Ji, Y., Liu, P., Li, Y., & Nebiyou Bekele, B. (2010). A modified toxicity probability interval method for dose-finding trials. Clinical Trials, 7(6), 653-663.
  27. Bekele, B. N., Li, Y., & Ji, Y. (2010). Risk‐Group‐Specific Dose Finding Based on an Average Toxicity Score. Biometrics, 66(2), 541-548.
  28. Ji, Y., & Bekele, B. N. (2009). Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomes. Biometrics, 65(3), 876-884.
  29. Wang, M., Oki, Y., Pro, B., Romaguera, J. E., Rodriguez, M. A., Samaniego, F., McLaughlin, P., Hagemeister, F., Neelapu, S., Copeland, A., Samuels, B. I., Loyer, E. M., Ji, Y., & Samuels, B. I. (2009). Phase II study of yttrium-90–ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 27(31), 5213-5218.
  30. Bekele, B. N., Ji, Y., Shen, Y., & Thall, P. F. (2007). Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics, 9(3), 442-457.
  31. Li, Y., Bekele, B. N., Ji, Y., & Cook, J. D. (2008). Dose–schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Statistics in medicine, 27(24), 4895-4913.
  32. Hu, B., Ji, Y., & Tsui, K. W. (2008). Bayesian estimation of inverse dose response. Biometrics, 64(4), 1223-1230.
  33. Fanale, M. A., Fayad, L. E., Pro, B., Samaniego, F., Zachariah, G., Nunez, C. A., Ji, Y., & Younes, A. (2008). A phase I study of bortezomib in combination with ICE (BICE) in patients with relapsed/refractory classical Hodgkin lymphoma.
  34. Ji, Y., Li, Y., & Yin, G. (2007). Bayesian dose finding in phase I clinical trials based on a new statistical framework. Statistica Sinica, 531-547.
  35. Ji, Y., Li, Y., & Nebiyou Bekele, B. (2007). Dose-finding in phase I clinical trials based on toxicity probability intervals. Clinical Trials, 4(3), 235-244.
  36. Yin, G., Li, Y., & Ji, Y. (2006). Bayesian Dose‐Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios. Biometrics, 62(3), 777-787.